PURE Bioscience Forms Advisory Panel

Tom Ridge, Tommy G. Thompson among Inaugural Members

SAN DIEGO, Calif., September  01, 2009 – PURE Bioscience (NASDAQ: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, announced today the inaugural members of its newly formed Advisory Panel: Tom Ridge, first Secretary of the U.S. Department of Homeland Security and former Governor of Pennsylvania; Scott M. Russell, Ph.D., Professor of Poultry Processing and Products Microbiology, Poultry Science Department of the University of Georgia; and Tommy G. Thompson, former U.S. Secretary of Health and Human Services and former four-term Governor of Wisconsin.  Thompson recently stepped down from the PURE Board and joined the Advisory Panel.

Michael L. Krall, President and CEO of PURE Bioscience, stated, “We are pleased to announce the formation of the Advisory Panel and are honored to welcome its first members.  As we continue to validate additional applications for SDC in many diverse industries and work to develop strategies for each industry, we believe it will be invaluable to receive guidance from key leaders in various market segments.  Access to the experience, vision and contacts of leaders like Tom Ridge, Dr. Scott Russell and Tommy Thompson exponentially strengthens our business development program.”

Secretary Tommy G. Thompson commented on his appointment to the Advisory Panel, “I’m enthusiastic about the opportunity to continue to work with PURE by serving on the Advisory Panel.  Although the profile in the August 23^rd edition of the Sunday New York Times certainly helped raise awareness of SDC-based products, we still have a lot of work to do.  I remain committed to my mission of helping to educate government agencies, businesses and consumers about the remarkable benefits of SDC-based products and how they can be instrumental in preventing transmission of dangerous human pathogens like MRSA, Norovirus and the pandemic H1N1 swine flu virus.” 

Secretary Tom Ridge stated, “The unique chemical nature of SDC as a stable, powerful yet non-toxic antimicrobial molecule renders it critically important to the field of public safety.  A multitude of possible applications exists for SDC in domestic and international industry and government, including the military, and I welcome the prospect of working with PURE Bioscience to accelerate its business strategy to commercialize SDC as a platform technology.”

Dr. Russell, added, “Silver dihydrogen citrate has immense market potential when formulated as a recently EPA-registered food contact surface sanitizer as well as when used as a processing aid in poultry processing and other types of food production operations.  SDC’s advantages in efficacy and safety translate to increased efficiency and cost savings for production, packaging and distribution companies.  SDC could also provide much-needed protection for consumers.  I am excited about the opportunity to be involved with the introduction of PURE to the food processing market and look forward to assisting PURE with the R&D, market study and implementation of SDC as a next generation solution to the challenges faced in the industry.”

Patented Molecule Provides Powerful Protection

SDC is an electrolytically generated source of stabilized ionic silver. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, low toxicity and the inability of bacteria to form a resistance to it. The first new disinfectant active ingredient to be registered by the EPA in more than 30 years, SDC-based disinfectants are antiviral, antifungal and antibacterial, including a 30-second kill and 24-hour residual protection against standard indicator bacteria and a two-minute kill claim on MRSA (Methicillin-resistant Staphylococcus aureus), CA-MRSA, PVL-MRSA and VRE (Vancomycin resistant Enterococcus faecium).  Moreover, SDC-based disinfectants are odorless, colorless, non-corrosive, non-flammable and are compatible with other disinfecting and cleaning chemicals.  In addition, SDC-based disinfectants are included on the list published by the U.S. Environmental Protection Agency (EPA) of antimicrobial products effective against the 2009 H1N1 flu strain (“swine flu”) based on their effectiveness against other influenza A virus strains.  Disinfectants containing PURE’s SDC antimicrobial also meet the recommendation by the CDC for infection control of H1N1 in both home and healthcare settings.

About PURE Bioscience

PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges.  PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety.  Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds.  As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it.  PURE is headquartered in El Cajon, California (San Diego metropolitan area).  Additional information on PURE is available at www.purebio.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project,” "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.